SecBot SecBot

REVB

REVELATION BIOSCIENCES, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001810560 Biotech & Drug Discovery
$3.82 −0.44 (−10.43%)
Nov 16 4:00 PM ET · prev $4.26
Market cap
$3.0M
Nano cap
Median target
🔒 Subscribers only
1 year
+8.2%
from $3.53 · Nov 17
30 days
+16.4%
from $3.28
52-week range
$3.20–26.57
−86% from high · low Dec 31
Avg volume 20D
21.6K
Oct 20 spike 156.0K
Short interest
12.8K
≈1.9% of shares · +93.7%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
4
analyzed by SecBot
SecBot read BEARISH 3 reports · 90 days
Balance 1 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/3

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 1 trimmed or exited.

  • Short sellersBUILDING

    Short interest +93.7% to 12.8K shares. 1.0 days to cover, ≈1.9% of shares.

  • TrendDOWNTREND

    25% below its 50-day average.

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 17, 2026
Rolke James
Chief Executive Officer
Aug 17, 2026
AWARD208,076 sh
Aug 17, 2026
ROPER JESS
Director
Aug 17, 2026
AWARD32,011 sh
Aug 17, 2026
Chawla Lakhmir S
Director
Aug 17, 2026
AWARD32,011 sh
Aug 17, 2026
Zygmont Chester Stanley III
Chief Financial Officer
Aug 17, 2026
AWARD208,073 sh
Aug 17, 2026
Zygmont Chester Stanley III
Chief Financial Officer
Aug 17, 2026
GIFT208,073 sh
Aug 17, 2026
CARVER JENNIFER
Director
Aug 17, 2026
AWARD32,011 sh
Apr 30, 2026
Rolke James
Chief Executive Officer
Apr 30, 2026
TAX W/H$11.4K
Apr 30, 2026
Zygmont Chester Stanley III
Chief Financial Officer
Apr 30, 2026
TAX W/H$14.6K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next QNoneNoneNo data$0.00
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
12,792
shares short
+93.7%
vs prior settlement
1.0
days to cover
≈1.9%
of shares outstanding
Trading halts
Oct 20, 2026Volatility PauseResumed
Oct 19, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
Revelation Biosciences filed an 8-K to disclose its intention to use social media channels (X, Facebook, Instagram…
8-K · Impact 2/10
Nov 5, 2026 SEC
Revelation Biosciences reported Q3 2026 net loss of $3.3M ($5.92 per share) vs $1.9M ($49.51 per share) in Q3 2025…
8-K · Impact 4/10
Nov 4, 2026 Earnings calendar
REVB Q3 2026 Earnings Scheduled · 2026-11-04
Aug 19, 2026 SEC
Revelation Biosciences granted restricted stock awards to CEO James Rolke (208,076 shares) and CFO Chester Zygmont…
8-K · Impact 3/10
Aug 17, 2026 Insider
Rolke James was granted 208,076 shares
Chief Executive Officer
Aug 17, 2026 Insider
ROPER JESS was granted 32,011 shares
Director
Aug 17, 2026 Insider
Chawla Lakhmir S was granted 32,011 shares
Director
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC · TRIM
17,192 shares ($17.7K)

SecBot reports

4 filings · 0 bullish · 1 bearish · 3 neutral
All REVB filing & press-release reports (4)